Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Proceedings of the 8th Global Arthritis Research Network (GARN) Meeting and 1st Bio-Rheumatology International Congress (BRIC)

Oral presentation

Synovial fibroblasts display an uncontrolled inflammatory and tissue destructive response to TNF-α

George D Kalliolias12*, Janice Chen1, Galina Grigoriev1 and Lionel B Ivashkiv13

  • * Corresponding author: George D Kalliolias

Author Affiliations

1 Research Department, Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, 10021, USA

2 Medicine, Weill Cornell Medical College, New York, NY, 10021, USA

3 Graduate Program in Immunology and Microbial Pathogenesis, Weill Cornell Graduate School of Medical Sciences, New York, NY, 10021, USA

For all author emails, please log on.

Arthritis Research & Therapy 2012, 14(Suppl 1):O36  doi:10.1186/ar3591


The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/14/S1/O36


Published:9 February 2012

© 2012 Kalliolias et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

Synovial fibroblasts are key players in the pathogenesis of Rheumatoid Arthritis (RA) and potentially attractive treatment targets. Upon activation within the joint's inflammatory milieu, they gain a transformed phenotype and produce pro-inflammatory cytokines (mainly IL-6) and tissue destructive enzymes [1].

Materials and methods

Synovial fibroblasts were isolated via enzymatic processing from synovial tissues obtained from patients with RA or Osteoarthritis (OA). Synovial fibroblasts (passages 2-4) were stimulated with TNF-α (10 ng/ml) only on day 1. The expression of TNF-α-target genes was measured by qPCR in time course experiments (1, 3, 6, 24, 48, 72, 96 and 120 hours after TNF-α stimulation).

Human macrophages (Mϕ) generated in vitro (blood derived CD14+ cells stimulated for 48 h with M-CSF) were used in similar time course experiments as controls.

Results

In Mϕ it was observed a rapid (within 1-3 hours) induction of TNF-α-target genes (including TNF-a, IL-1β, IL-6 and IL-8) that was restrained back to the baseline within a few hours (3-24 hours depending on the gene). In stark contrast, synovial fibroblasts displayed a remarkably more sustained response to TNF-α. IL-6 mRNA expression was induced within a few hours by TNF-α, and induction increased continuously for 72-96 h despite the absence of any further exogenous TNF-α stimulation. The levels of IL-6 mRNA induced by TNF-α in synovial fibroblasts were substantially higher compared to human Mϕ, suggesting that within the joint microenvironment, synovial fibroblasts and not Mϕ are the main source of IL-6. By adding the supernatants from 96 h TNF-α-stimulated fibroblast cultures on unstimulated synovial fibroblasts, a similar robust induction of IL-6 mRNA was observed, suggesting that there is a TNF-α-induced soluble factor that mediates the sustained response. A similar pattern of sustained expression was observed for other TNF-α-target genes including IL-1β, IL-8 and MMPs. Interestingly, there was no difference between OA- and RA-derived synovial fibroblasts in their response to TNF-α.

Conclusions

In contrast to human Mϕ, synovial fibroblasts display a sustained inflammatory and tissue destructive response to TNF-α. Our observations suggest that synovial fibroblasts may lack the homeostatic mechanisms that control and terminate the effects of TNF-α on human Mϕ [2]. To support this hypothesis, further investigation is needed at the level of proximal and distal TNF-α signaling events and at the level of epigenetic regulation of TNF-α-target genes in synovial fibroblasts.

References

  1. Bartok B, Firestein GS:

    Immunol Rev. 2010, 233(1):233-55. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  2. Ivashkiv LB:

    Eur J Immunol. 2011, 41:2477-81. PubMed Abstract | Publisher Full Text OpenURL